Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. Co. is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient's immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The ADPT average annual return since 2019 is shown above.
The Average Annual Return on the ADPT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADPT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADPT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ADPT Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
